Method for administering the drug deprenyl so as to minimize the danger of side effects

• US 4,861,800 A
• Filed: 08/18/1987
• Issued: 08/29/1989
• Est. Priority Date: 08/18/1987
• Status: Expired due to Term

• Current Assignee: Somerset Pharmaceuticals, Inc. (Pfizer Inc.)
• Original Assignee: Somerset Pharmaceuticals, Inc. (Pfizer Inc.)
• Inventors: Buyske, Donald A.
• Primary Examiner(s): Friedman, Stanley J.
• Application Number:
  US07/086,795
• Time in Patent Office: 742 Days
• Field of Search: 514/646
• US Class Current: 514/646
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 9/7069 obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

The monoamine oxidase inhibitor drug L-deprenyl (phenylisopropyl methyl propynyl amine) may be safely and conveniently used for the treatment of mental depression, Parkinson'"'"'s or Alzheimer'"'"'s Disease in a formulation applied to the skin of the patient. In this way the danger of side reaction due to the consumption of foods containing tyramine (the cheese effect) is minimized. Unlike other monoamine oxidase drugs, L-deprenyl does not cause skin irritation when used in this way.

Claims

1. A method for the treatment of Parkinson disease or Alzheimer disease in a human patient, comprising maintaining in contact with the skin of said patient a quantity of L-deprenyl or a salt thereof in a form permitting migration of said L-deprenyl or salt thereof through the skin of said patient into the bloodstream of the patient in an amount effective for said treatment and to produce a therapeutically effective amount of deprenyl within the blood supply to the brain of said patient.

2. A method, according to claim 1, wherein said L-deprenyl or salt thereof is mixed with an excipient before being applied to the skin of said patient.

3. A method, according to claim 2, wherein all excipients in combination cause the L-deprenyl content of the mixture to migrate into the bloodstream of the patient at a controlled rate, whereby at least said therapeutically effective amount of L-deprenyl is maintained in the blood supply to the brain of said patient continuously throughout a time interval.

4. A method, according to claim 3, wherein said mixture containing L-deprenyl is contained within a patch structure adapted for convenient affixation to a part of the body of said patient in such a manner as to maintain contact between the skin of said patient and said mixture containing L-deprenyl during said time interval.

5. A method, according to claim 4, wherein said time interval is at least one day.

6. A method, according to claim 5, wherein said controlled rate is between 5 and 50 mg of L-deprenyl per day.

7. A method according to claim 6 wherein said controlled rate is at least about 30 mg of L-deprenyl per day.